https://www.selleckchem.com/products/tcpobop.html
echanistic combination immunotherapy with PD-L1/PD-1 blockade that remodels innate and adaptive immune cells.Preclinical models of cancer have demonstrated enhanced efficacy of cell-cycle checkpoint kinase inhibitors when used in combination with genotoxic agents. This combination therapy is predicted to be exquisitely toxic to cells with a deficient G1-S checkpoint or cells with a genetic predisposition leading to intrinsic DNA replication stress, as these cancer cells become fully dependent on the intra-S and G2-M checkpoints for DNA
Like
Comment
Share
